JP2018508567A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508567A5
JP2018508567A5 JP2017555423A JP2017555423A JP2018508567A5 JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5 JP 2017555423 A JP2017555423 A JP 2017555423A JP 2017555423 A JP2017555423 A JP 2017555423A JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5
Authority
JP
Japan
Prior art keywords
antigen
composition
sequence encoding
nucleotide sequence
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017555423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508567A (ja
JP6647315B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/012496 external-priority patent/WO2016112195A1/en
Publication of JP2018508567A publication Critical patent/JP2018508567A/ja
Publication of JP2018508567A5 publication Critical patent/JP2018508567A5/ja
Application granted granted Critical
Publication of JP6647315B2 publication Critical patent/JP6647315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017555423A 2015-01-09 2016-01-07 組み合わせ免疫療法のための方法および組成物 Active JP6647315B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562101969P 2015-01-09 2015-01-09
US62/101,969 2015-01-09
US201562150236P 2015-04-20 2015-04-20
US62/150,236 2015-04-20
PCT/US2016/012496 WO2016112195A1 (en) 2015-01-09 2016-01-07 Methods and compositions for combination immunotherapy

Publications (3)

Publication Number Publication Date
JP2018508567A JP2018508567A (ja) 2018-03-29
JP2018508567A5 true JP2018508567A5 (enExample) 2019-02-14
JP6647315B2 JP6647315B2 (ja) 2020-02-14

Family

ID=56356431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555423A Active JP6647315B2 (ja) 2015-01-09 2016-01-07 組み合わせ免疫療法のための方法および組成物

Country Status (9)

Country Link
US (1) US11352642B2 (enExample)
EP (1) EP3242940B1 (enExample)
JP (1) JP6647315B2 (enExample)
KR (1) KR102193635B1 (enExample)
CN (2) CN113456812B (enExample)
AU (1) AU2016205215B2 (enExample)
CA (1) CA2974237C (enExample)
IL (1) IL253341B (enExample)
WO (1) WO2016112195A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
CA3030451C (en) 2016-07-15 2023-09-05 Etubics Corporation Compositions and methods for alphavirus vaccination
EP3484509A4 (en) * 2016-07-15 2020-03-25 Etubics Corporation COMPOSITIONS AND METHODS FOR VACCINATION AGAINST FLAVIVIRUS
US11422127B2 (en) 2016-12-07 2022-08-23 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
US11566077B2 (en) * 2017-01-17 2023-01-31 The University Of Chicago Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
US11020467B2 (en) 2017-05-26 2021-06-01 Etubics Corporation Combination immunotherapies comprising IL-15 superagonists
RU2020100072A (ru) * 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
US11866731B2 (en) 2017-11-10 2024-01-09 Chineo Medical Technology Co., Ltd Modified immune cells and uses thereof
US11573230B2 (en) 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
EP3743102A1 (en) * 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
JP2021520414A (ja) * 2018-04-04 2021-08-19 アルティミューン インコーポレーティッド Ｔ細胞を誘発するワクチン組成物の組合せ及びその使用
BR112021004417A2 (pt) * 2018-09-10 2021-06-01 Berg Llc métodos para tratar câncer pela inibição de enzima e2 k de conjugação de ubiquitina (ube2k)
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
CN115066499A (zh) * 2019-12-30 2022-09-16 格雷菲克斯公司 用于基因转移载体的高效产生的培养系统
KR102371663B1 (ko) * 2020-01-21 2022-03-04 코오롱생명과학 주식회사 아데노바이러스 벡터
CN116059339B (zh) * 2021-11-04 2023-09-22 元本(珠海横琴)生物科技有限公司 一种治疗和预防癌症的药物和应用
CN117110607B (zh) * 2023-09-16 2024-01-26 鲁东大学 一种检测副溶血性弧菌的组合物及其应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US820079A (en) 1903-07-15 1906-05-08 Auto Manual Piano Action Company Musical instrument.
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
ATE421888T1 (de) 1997-08-13 2009-02-15 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
ES2217585T3 (es) 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
EP1447414B1 (en) 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonist peptides of carcinoembryonic antigen (CEA)
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU774076C (en) * 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
US7009042B1 (en) 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
CA2388301C (en) * 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2002008436A2 (en) * 2000-07-20 2002-01-31 Genstar Therapeutics Corporation Mini-adenoviral vector system for vaccination
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1417353A4 (en) 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
US8236776B2 (en) 2002-04-09 2012-08-07 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
CN1548537B (zh) 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
EP1622937A2 (en) 2003-05-05 2006-02-08 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Synthetic gene encoding human carcinoembryonic antigen and uses thereof
US8207314B2 (en) 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
EP1649020B1 (en) 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
CA2548347A1 (en) * 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
JP4814800B2 (ja) * 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9592284B2 (en) 2004-04-28 2017-03-14 The Trustees Of The University Of Pennsylvania Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
US8012468B2 (en) 2004-06-11 2011-09-06 Catholic Universtiy Industry Academic Cooperation Foundation Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same
KR20070068460A (ko) 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
EP1974044B1 (en) 2005-12-12 2011-01-26 CANJI, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
US20100055069A1 (en) 2006-04-21 2010-03-04 Transgene S.A. Hpv-18-based papillomavirus vaccines
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
NZ582823A (en) 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US20150182621A1 (en) 2009-04-28 2015-07-02 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA2840937A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
AU2014340201B2 (en) * 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
JP6670244B2 (ja) * 2014-01-07 2020-03-18 バビタ アグラワル 免疫調節組成物及びその使用法
WO2015123532A1 (en) 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
WO2015127027A1 (en) 2014-02-20 2015-08-27 Wayne State University Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Similar Documents

Publication Publication Date Title
Evans et al. Immune suppression and colorectal cancer
Eriksson et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
Li et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Van der Jeught et al. Targeting the tumor microenvironment to enhance antitumor immune responses
Dammeijer et al. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Finn Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic
CA2974237C (en) Methods and compositions for combination immunotherapy
Zamarin et al. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
JP2018502922A5 (enExample)
JP2019521099A (ja) Ｈｅｒ２／ｎｅｕを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
Biegert et al. Current development in adenoviral vectors for cancer immunotherapy
CN106029889A (zh) 表达免疫细胞刺激受体激动剂的腺病毒
JP2019508044A5 (enExample)
Gildener-Leapman et al. Tailored immunotherapy for HPV positive head and neck squamous cell cancer
Kitagawa et al. An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model
Cervera-Carrascon et al. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
WO2017100338A4 (en) Improved compositions and methods for viral delivery of neoepitopes and uses thereof
Ge et al. Emerging therapeutic strategies of different immunotherapy approaches combined with PD-1/PD-L1 blockade in cervical cancer
Han et al. AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo
Long et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
Chen et al. Current progress in immunotherapy of nasopharyngeal carcinoma
Chai et al. Co‐immunization with L‐Myc enhances CD8+ or CD103+ DCs mediated tumor‐specific multi‐functional CD8+ T cell responses
Fujita et al. Inhibition of transforming growth factor-β–mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types
Ahn et al. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model
Ding et al. Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors